SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors eagerly await earnings results, with community chatter focused on iPhone sales and forward guidance. Some anticipate a positive catalyst for a breakout, while others express concerns about valuation and potential downside, especially given mixed reactions to other big tech earnings this week. The stock's reaction post-earnings will likely set the tone for market sentiment.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending following its earnings release, with community members closely watching for sustained gains. Discussions revolve around AWS growth, overall profitability, and whether the stock can maintain its upward momentum or if profit-taking will lead to a reversal, similar to other tech stocks.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy's stock is volatile, with community members expressing concerns about margin calls and significant losses, while others remain bullish, anticipating a recovery. Discussions revolve around Bitcoin's impact on MSTR's profitability, especially considering Bitcoin's performance during the last quarter. Some traders speculate on earnings and potential S&P 500 inclusion, while others question the company's strategy and criticize its premium over Bitcoin.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors digest its latest earnings report, which featured better-than-expected revenue and EPS, alongside a rise in daily active users. The community is focused on the company's growth prospects and valuation, with some expressing concerns over user growth and heavy moderation, while others point to potential for long-term gains and a possible short squeeze. Hedge fund activity has also spurred conversation, as institutional investors have been increasing their positions in the company.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending as investors react to an analyst upgrade from JP Morgan citing potential in Base monetization and USDC yield opportunities. Community chatter suggests a possible run to $400, while others express skepticism based on past earnings performance, and anticipate volatility ahead of the Q3 report. The stock's recent decoupling from Bitcoin's price action is also being noted.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is trending amidst anticipation for upcoming earnings and discussions around interest rate cuts and their potential impact on the housing market. Community members are actively debating whether the stock is poised for a squeeze, with some pointing to high short interest, while others express frustration with the stock's price action despite seemingly positive catalysts. The company's acquisitions and integration of Redfin and Mr. Cooper are also key talking points, as investors assess the long-term potential of a vertically integrated homeownership platform.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to recent Q3 earnings optimism and discussions surrounding its legal battle with the Centers for Medicare & Medicaid Services (CMS) with some investors believing the stock is currently undervalued. The community is actively debating the potential impact of the CMS case outcome and eagerly awaiting earnings results to see if the company's growth trajectory will continue. Discussions also involve upcoming pipeline programs and revenue growth projections.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

DXCM is trending amid mixed sentiment following earnings and news of a leadership transition. While some investors see a buying opportunity due to growth in key markets and a raised full-year revenue outlook, others are concerned about margin pressures, competition, and product quality, particularly with the G7 sensor; the community is actively debating the stock's near-term trajectory.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the Platform and Devices segments. The Platform segment includes digital advertising and related services including the demand-side platform and content distribution services such as subscription and transaction revenue shares, media and entertainment promotional spending, the sale of premium subscriptions, and the sale of branded channel buttons on remote controls. The Devices segment is involved in the sale of streaming players, audio products, smart home products, and accessories that are sold through retailers and distributors, as well as directly to customers through the company’s website. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending amid mixed reactions to its recent earnings report, despite the company meeting revenue expectations and raising its 2025 outlook. The community is debating whether the positive earnings justify the stock's current price, with some citing strong guidance and potential for growth in streaming hours and ad revenue, while others express concerns about the company's long-term profitability and competition. Discussions also include potential buy-out rumors and technical analysis, as the stock struggles to break through the \$100 mark.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to community discussion around earnings and a recent offering, with debates focusing on the significance of new deals and the company's growth potential. Bulls emphasize the disruptive nature of GSIT's technology and potential partnerships, while bears express concerns about disappointing results and valuation. Some investors speculate about a possible buyout or strategic investment from larger players in the semiconductor industry.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>A takeover or a large partnership was reportedly on the table for the company.</li><li>According to a report from Seeking Alpha, citing Stat News, the nature of the potential agreement, while unclear, is one of “significant scope.”&nbsp;</li><li>Moderna has been seeking to expand its portfolio since COVID-19 infections dropped globally. &nbsp;</li></ul>Shares of Moderna (MRNA) jumped 17% on Thursday afternoon following reports that the company held talks with at least one large drugmaker.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/news/4511489-moderna-gains-on-report-it-held-talks-with-at-least-one-large-drugmaker">report</a> from Seeking Alpha, citing Stat News, a takeover or a large partnership was being considered for the company. The nature of the potential agreement, while unclear, is one of “significant scope,” the report added. &nbsp;<h2 class="st-heading-2">Moderna’s Weakening Sales</h2>In August, the vaccine maker lowered its full-year revenue guidance to a range of $1.5 billion to $2.2 billion, reflecting a $300 million reduction at the high end of the range.For the second quarter, the company reported revenues of $142 million, down from the $241 million reported in the corresponding quarter of 2024. The company attributed the revenue drop to lower COVID-19 vaccine sales. It noted that its demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons, due to the seasonal nature of the infection.Sales of Moderna’s COVID-19 vaccine came in at $114 million in the three months through the end of June, while its Respiratory Syncytial Virus vaccine sales were negligible.The company has been seeking to expand its portfolio since COVID-19 infections dropped globally from their peak in the early 2020s. The company hit a peak yearly revenue of $19.3 billion in 2022, when COVID-19 &nbsp;infections were high, which then dropped to $3.2 billion in 2024. The shares have borne the brunt, dropping over 57% in the past five years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user sounded cautious about the company’s upcoming earnings.<stembedurl>https://stocktwits.com/Galba/message/634362215</stembedurl>Since the start of the year, the company’s shares have declined by approximately 30%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bmy-ceo-expects-cancer-drug-opdivo-to-drive-strong-sales-in-2025/cLG8bFRR3xp">BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Stock Rallies On Reports Of Company Entering Talks With A Drugmaker For A Potential Deal

According to a report from Seeking Alpha, citing Stat News, Moderna has held talks with at least one large drugmaker. 

Equity

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

mRNA Vaccine For Birth Defects Didn't Work Well, Won't Be Continued: Moderna

mRNA Vaccine For Birth Defects Didn't Work Well, Won't Be Continued: Moderna Moderna - which has been around less than 10 years and 'somehow' convinced the government to mandate their mRNA jabs for...

Wall Street's top analyst calls for the week of October 20, 2024

Yahoo Finance looks at Wall Street's top analyst call for the week of October 20, 2024. 0:00 Ebay, Deckers Outdoor, Intel October 24, 2025 1:37 Tesla, Zions Bancorp, Moderna October 23, 2025 3:25...

Moderna (MRNA) Outperforms Broader Market: What You Need to Know

Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

<ul class="summary-bullets"><li>Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a large Phase 3 trial, prompting the company to end its congenital CMV program.</li><li>The biotech will continue testing the vaccine in bone marrow transplant patients, where CMV reactivation can cause serious complications, and said no safety concerns were identified.</li><li>Moderna reaffirmed its 2025 guidance and breakeven goal for 2028, noting the vaccine was expected to be cash-flow negative that year.</li></ul>Moderna Inc. shares fell 4% in after-hours trading on Wednesday after the biotech company said its investigational cytomegalovirus (CMV) vaccine, mRNA-1647, failed to meet its primary efficacy endpoint in a late-stage trial.<h2 class="st-heading-2">Phase 3 Trial Misses Target</h2>The Phase 3 trial was designed to determine if the vaccine can prevent CMV infection among seronegative women aged 16-40. Moderna stated that the vaccine efficacy was substantially below the company's expectations and fell between 6 and 23% depending on the case definition used. The company will not continue the development of mRNA-1647 for the prevention of congenital CMV.“Today's announcement is disappointing for families and healthcare professionals who have been eagerly awaiting a CMV vaccine to prevent congenital CMV,” said CEO Stephane Bancel in a statement. “We will share full results with the scientific community in hopes that our learnings contribute to the continued pursuit of a CMV vaccine.”<h2 class="st-heading-2">Focus Shifts To Transplant Patients</h2>Moderna will further evaluate mRNA-1647 in a Phase 2 trial for bone marrow transplant recipients, who can experience serious complications when CMV is reactivated. The company said it will investigate the vaccine’s ability to suppress CMV reactivation in this high-risk population.The company said mRNA-1647 was well-tolerated with no safety concerns identified by the trial’s monitoring board.<h2 class="st-heading-2">No Impact On Financial Outlook</h2>Moderna said the setback is not expected to impact its 2025 financial guidance or its path to breakeven in 2028. The company had expected low revenue for the CMV vaccine in the near term before investments in the market and for the product to be cash-flow negative in 2028.<h2 class="st-heading-2">Stocktwits Users Debate Cash Burn, Oncology Focus After Vaccine Failure</h2>On Stocktwits, retail sentiment for Moderna was ‘bearish’ amid ‘normal’ message volume.<figure class="image"><img style="aspect-ratio:978/137;" src="https://news.stocktwits-cdn.com/mrna_ss_jpg_45aec4f522.webp" alt="mrna ss.jpg" width="978" height="137"><figcaption>MRNA sentiment and message volume as of October 22 | Source: Stocktwits</figcaption></figure>One user suggested the company’s decision to discontinue the CMV program might actually help reduce its cash burn, saying the move could allow Moderna to concentrate more effectively on its oncology pipeline.<stembedurl>https://stocktwits.com/pfh_investing/message/633326630</stembedurl>Another user expressed concern that the company’s spending remained unsustainable, describing its cash burn as “endless.”<stembedurl>https://stocktwits.com/KK_KK/message/633344767</stembedurl>A third bearish user took a harsher view, warning that the stock could fall below $5, after revealing they held two sold naked calls expiring this week.<stembedurl>https://stocktwits.com/georgeyann/message/633359261</stembedurl><a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> has declined 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn

The biotech will continue testing the vaccine in bone marrow transplant patients, where CMV reactivation can cause serious complications, and said no safety concerns were identified.

Market Wrap- Top Stocks: Tesla, Intuitive Surgical

The earnings season has sent the market into a scramble. Strong reports from major banks last week sent the market soaring, followed by Tuesday's estimate miss from Netflix and electric-vehicle...

Moderna (MRNA) Dips More Than Broader Market: What You Should Know

Moderna (MRNA) closed at $26.85 in the latest trading session, marking a -2.33% move from the prior day.

Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.

R&D spending now can have big payoffs later for companies

Just how long have people been saying you have to spend money to make money"?Historians maintain that this particular proverb goes all that way back to the Roman playwright Titus Maccius Plautus, who...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MRNA News

MRNAModerna Inc